Keuze uit niet-synthetische kleurstoffen groter dankzij Colorcons petitie voor spirulinaextract
HARLEYSVILLE, Pa.–(BUSINESS WIRE)– Colorcon, Inc. heeft vandaag bekendgemaakt dat de FDA zijn Color Additive Petition (CAP 4C0300) heeft aangenomen. Colorcon diende deze petitie in voor goedkeuring van het gebruik van spirulinaextract in coatingformules voor voedingssupplementen, pillen en capsules voor de Amerikaanse markt. Het gebruik van spirulinaextract als kleuradditief biedt mogelijkheden voor een breder palet van vrijgestelde kleurstoffen, die vaak als ‘natuurlijk’ worden aangeduid.
Colorcons reageerde met de petitie op de almaar toenemende vraag van voedingssupplementproducenten naar natuurlijk verkregen pigmenten, en dan vooral naar de moeilijk te creëren diepblauwe kleuren. De FDA heeft na bestudering van Colorcons geactualiseerde veiligheidsonderzoek en bijkomende tests ingestemd met de uitbreiding van de productcategorieën waarvoor spirulinaextract mag worden gebruikt. Dit algenextract mag voortaan ook in farmaceutische producten en voedingssupplementen voor verkoop in de Verenigde Staten worden toegepast.
Non-synthetic Color Spectrum Expands as FDA Approves Colorcon’s Spirulina Extract Petition
HARLEYSVILLE, Pa.–(BUSINESS WIRE)– Colorcon, Inc. today announced the FDA’s approval of the Color Additive Petition (CAP 4C0300) submitted by Colorcon for the use of Spirulina Extract. This approval will allow the use of Spirulina Extract in coating formulations applied to dietary supplements, drug tablets and capsules marketed in the United States. Use of Spirulina Extract as a color additive provides opportunities for a wider palette of exempt (typically referred to as “natural”) colors, from solid blues, through to vibrant greens and purple shades.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150821005180/en/
Colorcon developed this petition in response to ever-increasing requests from dietary supplement manufacturers for more naturally derived pigment options, specifically stable blue colors, which are difficult to achieve. The FDA, after their review of Colorcon’s updated safety assessment and additional product stability testing performed by Colorcon, agreed to expand the range of product categories in which Spirulina Extract can be used to include all types of pharmaceutical and dietary supplement tablets in the United States.
“We are proud to be instrumental in expanding the use of Spirulina Extract, especially for use in the dietary supplement industry, said Kelly Boyer, Colorcon’s Film Coating General Manager. “Blue and green colors are difficult to achieve using previously approved “natural” colorants. Incorporating pigments that are more “natural” requires specialized formulation and extensive stability programs to obtain the best quality results, including acceptable shelf-life for the final coated tablets. With our globally recognized color
expertise, Colorcon will successfully utilize Spirulina Extract as a colorant across a broad range of applications, bringing an expanded spectrum of colors, with improved stability, to our customers.”
Information related to the approval is referenced in the Federal Register, USA, Docket Number
FDA-2014-C-1552.
Company Information
Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Best-in-class products and technologies are complemented by extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture. Focusing on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply. 19 technical service laboratories globally and over 1200 employees are dedicated to its customer base.
# # #
View source version on businesswire.com: http://www.businesswire.com/news/home/20150821005180/en/
Contacts
Richard Hayhurst Associates
Richard Hayhurst
+447711821527